Unexpected Animals That Use Tools

Scientists once thought that only humans and our closest relatives, chimps, were clever enough to use tools. But as our documenting of the natural world has gotten more detailed—and as we’ve becom

Website link :https://adquash.com/news_q.php?str=Unexpected-Animals-That-Use-Tools

Rapid tests to detect whether drinks have been spiked to be developed

RAPID tests to detect whether a drink has been spiked are to be developed. Staff in clubs and bars will also be given more training to help spot foul play. 1 Funding for Covid-style tests will help re

Website link :https://adquash.com/news_q.php?str=Rapid-tests-to-detect-whether-drinks-have-been-spiked-to-be-developed

XB-002 by Exelixis for Epithelial Ovarian Cancer: Likelihood of Approval

XB-002 is under clinical development by and currently in Phase II for Epithelial Ovarian Cancer. According to GlobalData, Phase II drugs for Epithelial Ovarian Cancer have a 38% phase transition succe

Website link :https://adquash.com/news_q.php?str=XB-002_by_Exelixis_for_Epithelial_Ovarian_Cancer:_Likelihood_of_Approval_904

RBD-1016 by Suzhou Ribo Life Sciences for Hepatitis B: Likelihood of Approval

RBD-1016 is under clinical development by Suzhou Ribo Life Sciences and currently in Phase II for Hepatitis B. According to GlobalData, Phase II drugs for Hepatitis B have a 36% phase transition succe

Website link :https://adquash.com/news_q.php?str=RBD-1016_by_Suzhou_Ribo_Life_Sciences_for_Hepatitis_B:_Likelihood_of_Approval_906

Samsung and Hyundai partner to integrate smart home and car technology

Samsung announced a partnership with Hyundai Motor Group to integrate Samsung SmartThings into connected Hyundai and Kia vehicles, including electric vehicles (EVs). The collaboration aims to create �

Website link :https://adquash.com/news_q.php?str=Samsung-and-Hyundai-partner-to-integrate-smart-home-and-car-technology

Law enforcement increasingly enlists artificial intelligence to fight crime

Back Print By Kerry Picket - The Washington Times - Wednesday, December 27, 2023 It’s not yet to the point of science fiction’s “Minority Report,” where police can arrest someone for “precri

Website link :https://adquash.com/news_q.php?str=Law-enforcement-increasingly-enlists-artificial-intelligence-to-fight-crime

UK drink-spiking laws to be “modernised” as campaigners call for specific criminal offence

A "clear" and "unequivocal" definition of spiking is one of the changes soon to be made The Home Office has announced its drink-spiking laws will be “modernised”. According to Sky News , the Crimi

Website link :https://adquash.com/news_q.php?str=UK-drink-spiking-laws-to-be-modernised-as-campaigners-call-for-specific-criminal-offence

Glofitamab by F. Hoffmann-La Roche for Non-Hodgkin Lymphoma: Likelihood of Approval

Glofitamab is under clinical development by F. Hoffmann-La Roche and currently in Phase I for Non-Hodgkin Lymphoma. According to GlobalData, Phase I drugs for Non-Hodgkin Lymphoma have a 74% phase tra

Website link :https://adquash.com/news_q.php?str=Glofitamab_by_F._Hoffmann-La_Roche_for_Non-Hodgkin_Lymphoma:_Likelihood_of_Approval_1181

PLX-51107 by Plexxikon for Graft Versus Host Disease (GVHD): Likelihood of Approval

PLX-51107 is under clinical development by Plexxikon and currently in Phase II for Graft Versus Host Disease (GVHD). According to GlobalData, Phase II drugs for Graft Versus Host Disease (GVHD) have a

Website link :https://adquash.com/news_q.php?str=PLX-51107_by_Plexxikon_for_Graft_Versus_Host_Disease_(GVHD):_Likelihood_of_Approval_1182

Tezepelumab by Amgen for Chronic Obstructive Pulmonary Disease (COPD): Likelihood of Approval

Tezepelumab is under clinical development by Amgen and currently in Phase II for Chronic Obstructive Pulmonary Disease (COPD). According to GlobalData, Phase II drugs for Chronic Obstructive Pulmonary

Website link :https://adquash.com/news_q.php?str=Tezepelumab_by_Amgen_for_Chronic_Obstructive_Pulmonary_Disease_(COPD):_Likelihood_of_Approval_1184

DSP-0187 by Jazz Pharmaceuticals for Narcolepsy: Likelihood of Approval

DSP-0187 is under clinical development by Jazz Pharmaceuticals and currently in Phase I for Narcolepsy. According to GlobalData, Phase I drugs for Narcolepsy have an 80% phase transition success rate

Website link :https://adquash.com/news_q.php?str=DSP-0187_by_Jazz_Pharmaceuticals_for_Narcolepsy:_Likelihood_of_Approval_1185

Lirilumab by Bristol-Myers Squibb for Refractory Multiple Myeloma: Likelihood of Approval

Lirilumab is under clinical development by Bristol-Myers Squibb and currently in Phase II for Refractory Multiple Myeloma. According to GlobalData, Phase II drugs for Refractory Multiple Myeloma have

Website link :https://adquash.com/news_q.php?str=Lirilumab_by_Bristol-Myers_Squibb_for_Refractory_Multiple_Myeloma:_Likelihood_of_Approval_1186